Advanced Hepatocellular Cancer Treated with Sorafenib and Novel Inflammatory Markers

ConclusionToday, as the standard first-line treatment of HCC has shifted to combinations with immunotherapy (IO), IO transportation is not possible in most countries of the world. However, there are also patients who achieve great survival with only sorafenib. The important point is to identify the biomarkers that predict which patient will benefit better from which treatment. With the markers in our study and a scoring system that can be obtained with these markers, it can be evaluated which patient will be given IO combination and which patient will be given only TKI treatment. We think that such a scoring system can be used to identify suitable patients, especially in countries where, for financial reasons, not every patient can access Immunotherapy. The advantage of these tests is that they are inexpensive, easily calculable and standardized.Trial RegistrationNumber and date of registration: 2021/2088, 01 –06-2021, retrospectively registered.
Source: Journal of Gastrointestinal Cancer - Category: Cancer & Oncology Source Type: research